Gender differences in renal responses to hyperglycemia and angiotensin-converting enzyme inhibition in diabetes

DAVID Z.I. CHERNEY, ETIENNE B. SOCHETT, and JUDITH A. MILLER

Division of Nephrology, Toronto General Hospital; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Endocrinology, Hospital for Sick Children; and Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada

Gender differences in renal responses to hyperglycemia and angiotensin-converting enzyme inhibition in diabetes.

Background. Diabetes mellitus reduces female gender-mediated protection against progression of renal disease but the mechanisms responsible for this loss of protection are unknown. The impact of gender on the diabetic hyperfiltration state has not previously been studied. Since hyperfiltration is a factor in the development of diabetic renal disease, and is influenced by hyperglycemia and renin-angiotensin system (RAS) blockade, we examined gender differences in the renal response to hyperglycemia and angiotensin-converting enzyme (ACE) inhibition in young males and females with uncomplicated type 1 diabetes mellitus.

Methods. Ten male and 12 female normoalbuminuric, normotensive, adolescents with type 1 diabetes mellitus were studied before ACE inhibition during clamped euglycemia and hyperglycemia, and then after 21 days treatment with enalapril (0.1 mg/kg daily × 1 week and then 0.1 mg/kg twice a day × 2 weeks).

Results. During clamped euglycemia, males exhibited significantly higher effective renal plasma flow (ERPF) and renal blood flow (RBF) and a lower renal vascular resistance (RVR). During clamped hyperglycemia, females exhibited reductions in ERPF and RBF, and increased RVR and filtration fraction (FF). Males exhibited no significant renal hemodynamic changes during hyperglycemia. After ACE inhibition treatment, both genders exhibited significant declines in arterial pressure, but only females displayed a reduction in glomerular filtration rate (GFR) and FF.

Conclusion. The renal responses to hyperglycemia and ACE inhibition appear to differ between male and female adolescents with uncomplicated type 1 diabetes mellitus. Hyperglycemia-induced changes in RVR and FF in women may account, at least in part, for the loss of gender-based protection in diabetic renal disease.

Key words: glomerular filtration rate, renin-angiotensin system, hyperfiltration state, gender, type 1 diabetes mellitus.

Received for publication January 27, 2005
and in revised form March 22, 2005
Accepted for publication May 5, 2005

© 2005 by the International Society of Nephrology
course of RAS blockade during euglycemic conditions, hypothesizing that any sex differences in the responses to these maneuvers could further our understanding of the impact of gender on the mechanisms that may underlie the predilection for developing diabetic renal disease.

METHODS

Subjects

The protocol was approved by the Research Ethics Board of the Hospital for Sick Children, Toronto, Canada. All patients and/or their parents gave informed consent. Twenty-two adolescents (10 males and 12 females) with type 1 diabetes mellitus were recruited from an ongoing longitudinal cohort study of ambulatory blood pressure monitoring at the Hospital for Sick Children. Participants who fulfilled the following inclusion criteria were asked to participate: duration of type 1 diabetes mellitus longer than 5 years, Tanner stage 2 to 5 puberty, normoalbuminuria [albumin excretion rate (AER) < 20 μg/min on two of three overnight urine collections obtained during the month prior to study], normal clinic blood pressure, and absence of chronic illness other than treated hypothyroidism or mild asthma.

Protocol and evaluations

During the 7-day prestudy phase of each experiment, subjects adhered to a sodium-replete (150 to 200 mmol/day) and protein-replete (1 to 1.5 g/kg/day) diet. Compliance was determined by measuring the urinary sodium and urea in overnight urine collections on days 5 and 6. Protein intake was calculated from the urea excretion using standard equations. Subjects were studied if the excretion of sodium and urea were 2 to 3 mmol/kg and 3 to 6 mmol/kg, respectively, in 24 hours. All subjects met these study criteria.

Euglycemic or hyperglycemic conditions were maintained for 10 to 12 hours preceding and during the investigations. Female subjects were studied during the early follicular phase of the menstrual cycle, determined by counting days of the menstrual cycle and measuring 17β-estradiol levels. None of the female subjects were taking oral contraceptive medications.

Studies were carried out on 3 separate days. Subjects were studied on day 1 during clamped euglycemia (blood glucose = 4 to 6 mmol/L) and on day 2 during clamped hyperglycemia (blood glucose = 9 to 11 mmol/L). After 21 days of enalapril (0.1 mg/kg daily × 1 week and then 0.1 mg/kg twice a day × 2 weeks), subjects were studied on day 3 using the same procedure during euglycemic conditions.

Subjects were admitted to the Clinical Investigation Unit at the Hospital for Sick Children the evening before each phase of the study. A 16-gauge peripheral venous cannula was inserted into a vein in one arm for infusion of glucose and insulin and a second blood sampling line was inserted into a vein in the contralateral arm. Blood glucose was measured every hour and the insulin infusion was adjusted to maintain euglycemia (4 to 6 mmol/L). Studies were conducted the following morning after an overnight fast with subjects lying in the supine position in a warm quiet room. A third intravenous line was inserted into the arm contralateral to the insulin infusion and was connected to a syringe infusion pump for infusions of inulin and paraminohippurate (PAH). Mean arterial pressure (MAP) and heart rate were measured prior to each blood sample throughout the study by an automated sphygmonanometer (Dinamapp). After collecting blood for inulin and PAH blank, a priming infusion containing 25% inulin (60 mg/kg) and 20% PAH (8 mg/kg) was administered. Thereafter, inulin and PAH were infused continuously at a rate calculated to maintain their respective plasma concentrations constant at 20 and 1.5 mg/dL. Subjects remained supine at all times. After a 90-minute equilibration period, blood was collected for inulin, PAH, and hematocrit. Blood was further collected each 20 minutes for 60 minutes, and glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were estimated by steady state infusion of inulin and PAH according to the calculation method described by Schnurr et al [16].

Sample collection and analytical methods

Blood samples collected for inulin and PAH determinations were immediately centrifuged at 3000 rpm for 10 minutes at 4°C. Plasma was separated, placed on ice, and then stored at −70°C before the assay. Inulin and PAH were measured in serum by colorimetric assays using anthrone and N-(1-naphthy) ethylenediamine, respectively. The mean of the final two baseline clearance periods represent GFR and ERPF, expressed per 1.73 m². Filtration fraction (FF) was determined as the ratio of GFR to ERPF. Renal blood flow (RBF) was calculated by dividing the ERPF by 1 hematocrit. Renal vascular resistance (RVR) was derived by dividing MAP by the RBF. Renal hemodynamic measurements were adjusted for body surface area (BSA).

Urinary AER was determined from three timed overnight urine collections. Urinary albumin concentration was determined by immunoturbidimetry [17]. Hemoglobin A1c (HbA1c) was measured by high-performance liquid chromatography (HPLC). The non-diabetic range for our laboratory is 4% to 6.3% [18].

Statistical analysis

The data were analyzed on the basis of gender. Results are presented as mean ± SEM. GFR, ERPF, and RBF were corrected for BSA. Between-group comparisons of
ACE inhibitors were determined by analysis of variance group differences in the response to hyperglycemia and methods (unpaired t test). Within-subject-and-between-group differences in the response to hyperglycemia and ACE inhibitors were determined by analysis of variance (ANOVA). All statistical analyses were performed using the statistical package SAS (SAS Institute Inc., Cary, NC, USA).

RESULTS
Baseline parameters: Clamped euglycemia and hyperglycemia

At baseline, the male and female groups were not significantly different in terms of age, Hba1c, body mass index (BMI), MAP, diabetes duration, urine sodium excretion, protein intake, or plasma renin activity (PRA). In females, 17β-estradiol levels were consistent with the early follicular phase (Table 1). During clamped euglycemia (Table 2), males exhibited significantly higher ERPF (*P = 0.048) and RBF (*P = 0.037), after correction for BSA. RVR was significantly lower in males (*P = 0.019). Although the GFR in males was numerically higher than in females, the values did not differ significantly. FF and MAP did not differ significantly between the two groups.

During clamped hyperglycemia compared to clamped euglycemia (Table 2), females exhibited a trend toward an elevation in GFR (*P = 0.07), a significant reduction in ERPF, and RBF with a significant rise in RVR and FF. In response to hyperglycemia, males did not display any significant alterations in renal hemodynamic function. The hyperglycemia-mediated renal hemodynamic changes in GFR (*P = 0.023), FF (*P = 0.014), and RVR (*P = 0.01) were significantly different in males compared to females (Figs. 1 to 3).

Response to ACE inhibitors

Males and females both exhibited significant reductions in MAP during clamped euglycemia post-ACE inhibition (Table 3). Females experienced a significant fall in GFR and FF with no significant change in ERPF, RBF, or RVR. In contrast, no significant change in any renal hemodynamic parameter was observed in males. The changes in GFR (*P = 0.04), FF (*P = 0.01), and RVR (*P = 0.01) responses to ACE inhibitors were significantly different in males compared to females (Figs. 1 to 3).

DISCUSSION

The protective effect of female gender in nondiabetic renal disease is diminished in diabetes mellitus [1–6], and

---

### Table 1. Baseline characteristics (mean ± SEM)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Female</th>
<th>Male</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age years</td>
<td>14.32 ± 1.64</td>
<td>15.40 ± 2.30</td>
<td>0.21</td>
</tr>
<tr>
<td>Body mass index kg/m²</td>
<td>24.59 ± 3.56</td>
<td>22.15 ± 1.88</td>
<td>0.07</td>
</tr>
<tr>
<td>Hemoglobin A₁c, %</td>
<td>8.56 ± 0.93</td>
<td>8.50 ± 1.2</td>
<td>0.89</td>
</tr>
<tr>
<td>Diabetes duration years</td>
<td>10.02 ± 2.61</td>
<td>11.54 ± 3.05</td>
<td>0.22</td>
</tr>
<tr>
<td>Protein intake g/kg/day</td>
<td>1.17 ± 0.04</td>
<td>1.21 ± 0.05</td>
<td>0.89</td>
</tr>
<tr>
<td>Urine Na⁺ mmol/day</td>
<td>144 ± 21</td>
<td>152 ± 18</td>
<td>0.23</td>
</tr>
<tr>
<td>Plasma renin activity ng angiotensin I/L/min</td>
<td>0.09 ± 0.002</td>
<td>0.08 ± 0.001</td>
<td>0.64</td>
</tr>
<tr>
<td>17β-estradiol pmol/L</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Mean arterial blood pressure mm Hg</td>
<td>76.23 ± 5.65</td>
<td>78.30 ± 9.16</td>
<td>0.64</td>
</tr>
</tbody>
</table>

### Table 2. Mean systemic and renal hemodynamic responses to hyperglycemia (mean ± SEM)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Female</th>
<th>Male</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean arterial blood pressure mm Hg</td>
<td>76.87 ± 7.51</td>
<td>78.04 ± 10.09</td>
<td>0.52</td>
</tr>
<tr>
<td>Glomerular filtration rate mL/min/1.73 m²</td>
<td>135.59 ± 43.96</td>
<td>144.37 ± 21.44</td>
<td>0.07</td>
</tr>
<tr>
<td>Effective renal plasma flow mL/min/1.73 m²</td>
<td>647.61 ± 122.65</td>
<td>589.35 ± 77.98</td>
<td>0.001</td>
</tr>
<tr>
<td>Filtration fraction</td>
<td>0.21 ± 0.05</td>
<td>0.24 ± 0.04</td>
<td>0.01</td>
</tr>
<tr>
<td>Renal blood flow mL/min/1.73 m²</td>
<td>1039.93 ± 171.34</td>
<td>935.37 ± 99.14</td>
<td>0.004</td>
</tr>
<tr>
<td>Renal vascular resistance mm Hg/L/min</td>
<td>75.89 ± 12.15</td>
<td>84.49 ± 14.28</td>
<td>0.01</td>
</tr>
</tbody>
</table>

---

![Fig. 1. Gender difference in glomerular filtration rate (GFR) responses to hyperglycemia and angiotensin-converting enzyme inhibitors (ACEI). The change (Δ) in GFR in response to hyperglycemia and ACE inhibitors in females and males with uncomplicated type 1 diabetes mellitus. *P < 0.05 versus response in females.](image-url)
During the clamped hyperglycemic phase of the study, females experienced significant decreases in ERPF and RBF, and an elevation in FF. The rise in FF suggests that the acute alteration in renal hemodynamic function was that of a greater increase in efferent relative to afferent arteriolar resistance. Such an effect, perhaps secondary to hyperglycemia-mediated RAS activation [10] would be associated with an increase in intraglomerular hydrostatic pressure. Interestingly, men exhibited little change in renal hemodynamic function in response to short-term hyperglycemia. We have previously shown that the vasoconstrictive response to RAS activation is blunted in females during the high estrogen phases of the menstrual cycle [11]. The augmented renal hemodynamic response to hyperglycemia in females in this study may have been partially because the studies in females were carried out during the follicular, low estrogen phase of the menstrual cycle. Although the mechanisms responsible for the increased renal hemodynamic response to hyperglycemia in females compared to males were not determined in this study, the predicted increase in glomerular capillary pressure may account for the clinical observation that female gender is not protective in diabetic nephropathy, glomerular capillary hypertension being a critical hemodynamic determinant of diabetic kidney disease progression [28–31].

The finding that ACE inhibitors resulted in beneficial reductions in GFR and FF only in females is consistent with studies in animals with and without experimental...
diabetes and humans with and without diabetes mellitus that examined the interaction between the RAS and estrogen [20, 32–37]. Animal models have demonstrated a reduction in serum ACE levels, tissue ACE activity and renal medullary ACE mRNA in response to estrogen [32]. The same study demonstrated an estrogen-mediated decrease in blood pressure, which was attributed to the observed reduction in RAS activity [32]. Studies in rat models have demonstrated that estrogen attenuates the responses to infusions of angiotensin II (Ang II) [33], and that 17β-estradiol replacement in ovariectomized diabetic rats reduces functional renal impairment, pathologic indices of glomerulosclerosis and interstitial fibrosis, urinary AER and transforming factor-β protein expression [38]. Gender-based differences in RAS function have also been shown in nondiabetic humans, including a blunted ERPF and FF response to Ang II infusion in women compared to men, especially in high estrogen states of the menstrual cycle [34]. In addition, alterations in components of the RAS and responsiveness of the RAS at the level of the peripheral vasculature [20] and renal vasculature [35] have been previously demonstrated. In humans with type 2 diabetes mellitus, hormone replacement therapy has been associated with a reduction in proteinuria and an increase in renal function [37]. Data from the Ramipril Efficacy in Nephropathy (REIN) study in nondiabetic renal disease showed that women experienced a significantly increased antiproteinuric effect from ACE inhibitors compared to men [36]. Women maintained on ramipril also exhibited a smaller decline in GFR over time, and a lower incidence of ESRD. The female gender-mediated augmented renal response to ACE inhibitors may be due to a synergistic effect of ACE inhibitors and estrogen on components of the RAS. Animal models examining the physiologic interaction between RAS blockade and estrogen have demonstrated synergistic effects leading to a reduction in deleterious vascular remodeling [39]. It is tempting to speculate that this phenomenon is also relevant to the hemodynamic effects of RAS activation. In the case of the present study, even though the experiments were carried out during the follicular phase, we noted an augmented response to ACE inhibitors in females, suggesting that any level of estrogen may act synergistically with RAS blockade. The influence of gender on progression of diabetic nephropathy has been examined in at least six outcome studies by different investigators [1–6]. The studies by Mangili et al [1], Orchard et al [2], and Jacobsen et al [3] found associations between male gender and worse outcomes as measured by albuminuria in the first two studies and the change in GFR in the third. The study by Orchard et al [2] reported a higher risk of nephropathy in women with a short duration of diabetes, and a lower risk with longer duration. Three other studies in a total of 1301 patients found no impact of gender on progression of diabetic renal disease [4–6]. From these studies it is apparent that women with diabetes mellitus as the cause of their chronic kidney disease do not have the same degree of protection against progression as women with nondiabetic renal disease [1–6, 40]. The present study has demonstrated that although females appeared to exhibit a protective renal hemodynamic response to ACE inhibitors, their response to hyperglycemia was deleterious, resulting in a physiologic profile that could favor the development and progression of disease.

This study has some important limitations. The sample size was small which probably contributed to the failure to reach statistical significance in some measurements (for example the GFR response to hyperglycemia in females). We attempted to correct for this by constructing homogenous groups and by careful prestudy preparation. In addition we used a paired design that allowed each subject to act as his/her own control, thereby decreasing variability and allowing us to reach some significant conclusions. Responses to RAS blockade can be influenced by prestudy differences in effective circulating volume [41]. We avoided this confounding effect by ensuring that our subjects were sodium replete, and by monitoring compliance with 24-hour urine collections for sodium excretion. Further, extreme hyperglycemia can activate the RAS through volume contraction induced by glucosuria. We protected against this by clamping blood glucose at 9 to 11 mmol/L in the hyperglycemic phase, below the threshold for glucosuria. Women exhibit variations in renal hemodynamic and RAS function throughout the menstrual cycle [11] or while taking oral contraceptive medications [42]. We reduced the impact of these factors by studying only female subjects who
were non-users of oral contraceptive medications, and only during the follicular (low estrogen) phase of the menstrual cycle. Finally, extrapolating from short-term physiologic studies to a long-term condition which progresses over years can be tenuous. However, our aim was to determine whether there are gender differences in the renal physiologic profile in response to the major factors that could conceivably promote or protect against progression of renal disease rather than to examine progression of disease over time, a project that would require a much larger, long-term study.

CONCLUSION

We have demonstrated gender differences in baseline renal hemodynamic function, the renal hemodynamic response to short-term hyperglycemia and to ACE inhibitors, in subjects with uncomplicated type 1 diabetes mellitus. These differences may be important in understanding the initiation and progression of diabetic renal disease in men and women. Our study suggests that women with type 1 diabetes mellitus respond more favorably to ACE inhibitors, with a beneficial reduction in GFR and FF, but that hyperglycemia may impact more negatively on their renal function, and may mitigate some of the protective effects of female gender. Glycemic control, although crucial in the management of all patients with type 1 diabetes mellitus, may be particularly important in women.

ACKNOWLEDGMENTS

This work was supported by an operating grant from the Canadian Institutes of Health Research (to Dr. J.A. Miller). Dr. David Cherney was supported by the Clinician Scientist Program of the University of Toronto Department of Medicine. The authors wish to thank Ms. Ria Dekker, study coordinator, and the nurses in the Clinical Investigation Unit, Hospital for Sick Children, for their invaluable assistance with the protocol.

Reprint requests to Dr. Judith A. Miller, Toronto General Hospital, 585 University Avenue, 8N-846 Toronto, Ontario, Canada, MG5 2N2. E-mail: judith.miller@utoronto.ca

REFERENCES

12. Lansang MC, Hollenberg NK: Renal perfusion and the renal hemodynamic response to blocking the renin system in diabetes: Are the forces leading to vasodilation and vasoconstriction linked? Diabetes 51:2025–2028, 2002
31. Lewis EJ, Hunisiek LG, Bain RP, Rohde RD: The effect of
angiotensin-converting-enzyme inhibition on diabetic nephropathy. 


